10-K · February 26, 2026
Denali Therapeutics reported substantial ongoing net losses totaling $512.5 million for the year ending December 31, 2025. Although the company continues to advance the development of its product pipeline, including…
Earnings analysis · 10-Q
DNLI earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Denali Therapeutics reported a net loss of $128.4 million in Q1 2026, an improvement from a loss of $133.0 million in Q1 2025. Despite entering the commercial phase with the FDA approval of AVLAYAH for Hunter syndrome…
Read full summary
Denali Therapeutics reported a net loss of $128.4 million in Q1 2026, an improvement from a loss of $133.0 million in Q1 2025. Despite entering the commercial phase with the FDA approval of AVLAYAH for Hunter syndrome in March 2026, the company continues to face significant operational losses and relies heavily on ongoing capital to sustain its strategies.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Improved Net Loss
Net loss narrowed to $128.4M in Q1 2026 from $133.0M in Q1 2025.
-
Successful Product Launch
Launch of AVLAYAH, FDA approved for Hunter syndrome, officially commenced in April 2026.
-
Cash Reserves
Cash, cash equivalents and marketable securities totaled approximately $1.05 billion as of March 31, 2026.
-
Reduced R&D Expenses
R&D expenses declined to $103.8M in Q1 2026, down from $116.2M in Q1 2025.
-
Increased G&A Expenses
G&A expenses increased by 14% to $33.5M compared to $29.4M in Q1 2025.
-
Funding Success
Received $200.0 million gross proceeds under a synthetic royalty agreement with Royalty Pharma following AVLAYAH’s approval.
What to watch
-
High Operating Losses
Continuing significant losses totaling $128.4M for Q1 2026 may impact sustainability.
-
Dependency on Product Success
Future revenue highly reliant on successful commercialization of AVLAYAH.
-
Competition and Market Acceptance Risks
AVLAYAH may struggle to establish adequate market acceptance due to competition and pricing pressures.
Management's outlook
No specific numeric guidance was provided for future quarters.
Earlier filings 4
10-Q · November 6, 2025
Denali Therapeutics reported a challenging third quarter for 2025 with no reported revenue and net losses increasing to approximately $126.9 million, up from $107.2 million in Q3 2024. The company also faced significant…
10-Q · August 11, 2025
Denali Therapeutics reported a continued lack of revenue for Q2 2025 but demonstrated a minor improvement in EPS, reported at -$0.72 against a consensus estimate of -$0.74. Operating expenses rose due to increased…
10-Q · May 6, 2025
Denali Therapeutics reported no revenue for Q1 2025, continuing an ongoing trend of significant operating losses with an EPS of -0.78, underperforming compared to prior loss periods and expectations. Operating expenses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.